Dominic Norton from Spitfire Network Services emphasises the importance of understanding the differences in fibre connectivity, highlighting the need to discern variations in quality and technology, while cautioning consumers against making choices based solely on price.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
Daniel Carbonell, TRI-HP Project Coordinator from SPF Institute for Solar Technology, explains how this EU funded project TRI-HP develops trigeneration systems based on heat pumps with natural refrigerants and multiple renewable sources, to provide heating, cooling and electricity to multi-family buildings.
Stephenson’s Rocket was a major driver of the last industrial revolution two hundred years ago. Will the UK PM, Johnson, be able to deliver a similar principle that will be recognised in two hundred years from now?
Wilke Reints, Managing Director of Siemens Mobility Limited’s Intelligent Traffic Systems business, turns our thoughts towards intelligent traffic systems (ITS) including comment on traffic volumes, air quality and electric vehicles.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains why hemp protein is gaining a reputation as nutraceutical product.
M. Danner and R.M Winglee from Department of Earth and Space Sciences, University of Washington, discuss the microscopic analysis of samples from penetrator impact craters.
Jane C Khoury & Shelley R Ehrlich from Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, highlight the consequences of foetal development in a “sweet” uterus – including the short- and long-term transgenerational outcomes.
Chief Scientist at Dynamic Object Language Labs Inc, Dr Paul Robertson explains how autonomous AI systems are key to achieving synergy between humans and robotics that can work together as a team.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
